Which has stronger earnings and valuation, BBIO or TLX?

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 33.51 -$724.93M -$3.74 N/A Telix Pharmaceuticals $803.79M 4.70 -$7.12M N/A N/A

Is BBIO or TLX more profitable?

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma -124.42% N/A -65.81% Telix Pharmaceuticals N/A N/A N/A

Does the media refer more to BBIO or TLX?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 9 mentions for BridgeBio Pharma and 7 mentions for Telix Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.69 beat Telix Pharmaceuticals' score of 0.29 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, TLX or AXSM?

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.70 -$7.12M N/A N/A Axsome Therapeutics $638.50M 18.84 -$183.17M -$3.73 N/A

Does the media favor TLX or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 12 mentions for Axsome Therapeutics and 7 mentions for Telix Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.89 beat Telix Pharmaceuticals' score of 0.29 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ELAN or TLX?

Telix Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elanco Animal Health $4.72B 2.63 -$232M -$0.50 N/A Telix Pharmaceuticals $803.79M 4.70 -$7.12M N/A N/A

Does the media refer more to ELAN or TLX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Elanco Animal Health. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 4 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Telix Pharmaceuticals' score of 0.29 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RDY or TLX?

Telix Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 88.51%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has higher valuation and earnings, RDY or TLX?

Dr. Reddy's Laboratories has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Reddy's Laboratories $3.58B 3.08 $456M $0.58 22.78 Telix Pharmaceuticals $803.79M 4.70 -$7.12M N/A N/A

Does the media prefer RDY or TLX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. Telix Pharmaceuticals' average media sentiment score of 0.29 beat Dr. Reddy's Laboratories' score of 0.25 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, TLX or ARWR?

Arrowhead Pharmaceuticals has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.70 -$7.12M N/A N/A Arrowhead Pharmaceuticals $829.45M 12.97 -$1.63M -$2.15 N/A

Does the media favor TLX or ARWR?

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.27 beat Telix Pharmaceuticals' score of 0.29 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Telix Pharmaceuticals (TLX) Competitors

$11.14 -0.64 (-5.43%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$11.21 +0.07 (+0.63%)

As of 07/10/2026 04:27 PM Eastern

Compare

TLX vs. BBIO, AXSM, ELAN, RDY, and ARWR

Should you buy Telix Pharmaceuticals stock or one of its competitors? MarketBeat compares Telix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telix Pharmaceuticals include BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

BridgeBio Pharma presently has a consensus target price of $92.90, suggesting a potential upside of 8.16%. Telix Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 88.51%. Given Telix Pharmaceuticals' higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	33.51	-$724.93M	-$3.74	N/A
Telix Pharmaceuticals	$803.79M	4.70	-$7.12M	N/A	N/A

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, BridgeBio Pharma had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 9 mentions for BridgeBio Pharma and 7 mentions for Telix Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.69 beat Telix Pharmaceuticals' score of 0.29 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market.

Summary

BridgeBio Pharma beats Telix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.70	-$7.12M	N/A	N/A
Axsome Therapeutics	$638.50M	18.84	-$183.17M	-$3.73	N/A

Telix Pharmaceuticals has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Telix Pharmaceuticals' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

In the previous week, Axsome Therapeutics had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 12 mentions for Axsome Therapeutics and 7 mentions for Telix Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.89 beat Telix Pharmaceuticals' score of 0.29 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals presently has a consensus price target of $21.00, indicating a potential upside of 88.51%. Axsome Therapeutics has a consensus price target of $259.05, indicating a potential upside of 10.80%. Given Telix Pharmaceuticals' higher possible upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Telix Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Axsome Therapeutics beats Telix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Telix Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.63	-$232M	-$0.50	N/A
Telix Pharmaceuticals	$803.79M	4.70	-$7.12M	N/A	N/A

Telix Pharmaceuticals has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Telix Pharmaceuticals	N/A	N/A	N/A

Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Elanco Animal Health. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 4 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Telix Pharmaceuticals' score of 0.29 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Elanco Animal Health currently has a consensus target price of $28.55, suggesting a potential upside of 14.94%. Telix Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 88.51%. Given Telix Pharmaceuticals' higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Elanco Animal Health beats Telix Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Dr. Reddy's Laboratories has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.08	$456M	$0.58	22.78
Telix Pharmaceuticals	$803.79M	4.70	-$7.12M	N/A	N/A

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Telix Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 88.51%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. Telix Pharmaceuticals' average media sentiment score of 0.29 beat Dr. Reddy's Laboratories' score of 0.25 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Telix Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 88.51%. Arrowhead Pharmaceuticals has a consensus target price of $87.27, indicating a potential upside of 14.23%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Arrowhead Pharmaceuticals has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.70	-$7.12M	N/A	N/A
Arrowhead Pharmaceuticals	$829.45M	12.97	-$1.63M	-$2.15	N/A

Telix Pharmaceuticals has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Telix Pharmaceuticals' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.27 beat Telix Pharmaceuticals' score of 0.29 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arrowhead Pharmaceuticals beats Telix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.78B	$3.71B	$7.09B	$12.66B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	N/A	21.64	27.42	24.53
Price / Sales	4.70	323.81	528.33	96.17
Price / Cash	264.21	143.33	48.47	60.03
Price / Book	9.06	8.41	10.88	6.38
Net Income	-$7.12M	$23.85M	$3.59B	$331.87M
7 Day Performance	-6.15%	-0.75%	-0.26%	0.37%
1 Month Performance	16.53%	8.68%	4.55%	0.59%
1 Year Performance	-30.24%	55.85%	29.86%	22.26%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.5741 of 5 stars	$11.14 -5.4%	$21.00 +88.5%	-30.2%	$3.78B	$803.79M	N/A	1,184	Analyst Forecast Gap Down
BBIO BridgeBio Pharma	2.4987 of 5 stars	$72.91 +1.2%	$92.90 +27.4%	+84.8%	$14.30B	$502.08M	N/A	400	Trending News Options Volume Gap Down
AXSM Axsome Therapeutics	3.3856 of 5 stars	$245.19 +1.7%	$258.95 +5.6%	+114.5%	$12.61B	$638.50M	N/A	380	News Coverage Analyst Forecast
ELAN Elanco Animal Health	4.0027 of 5 stars	$24.41 -1.3%	$28.55 +16.9%	+66.7%	$12.17B	$4.72B	N/A	9,400	Positive News
RDY Dr. Reddy's Laboratories	1.9278 of 5 stars	$14.51 -2.4%	N/A	-8.9%	$12.11B	$335.93B	25.01	27,527	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. BBIO, AXSM, ELAN, RDY, and ARWR

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. BBIO, AXSM, ELAN, RDY, and ARWR

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Do analysts prefer BBIO or TLX?

Do institutionals and insiders have more ownership in BBIO or TLX?

Which has stronger earnings and valuation, BBIO or TLX?

Is BBIO or TLX more profitable?

Does the media refer more to BBIO or TLX?

Which has more risk and volatility, BBIO or TLX?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Which has stronger valuation and earnings, TLX or AXSM?

Is TLX or AXSM more profitable?

Does the media favor TLX or AXSM?

Do analysts rate TLX or AXSM?

Which has more volatility and risk, TLX or AXSM?

Do institutionals & insiders have more ownership in TLX or AXSM?

Summary

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Which has stronger earnings and valuation, ELAN or TLX?

Is ELAN or TLX more profitable?

Which has more volatility & risk, ELAN or TLX?

Does the media refer more to ELAN or TLX?

Do institutionals & insiders believe in ELAN or TLX?

Do analysts prefer ELAN or TLX?

Summary

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Which has higher valuation and earnings, RDY or TLX?

Do institutionals & insiders have more ownership in RDY or TLX?

Is RDY or TLX more profitable?

Do analysts prefer RDY or TLX?

Does the media prefer RDY or TLX?

Which has more risk & volatility, RDY or TLX?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Do institutionals and insiders believe in TLX or ARWR?

Do analysts prefer TLX or ARWR?

Which has higher valuation and earnings, TLX or ARWR?

Which has more risk and volatility, TLX or ARWR?

Is TLX or ARWR more profitable?

Does the media favor TLX or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools